Wells Fargo & Company 2seventy Bio, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 26,399 shares of TSVT stock, worth $78,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,399

Previous 25,435 3.79%

Holding current value

$78,933

Previous $97,000 27.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.85 - $5.05 $3,711 - $4,868	964 Added 3.79%	26,399 $124,000
Q2 2024 Aug 13, 2024	BUY	$3.6 - $5.79 $12,895 - $20,739	3,582 Added 16.39%	25,435 $97,000
Q1 2024 May 10, 2024	BUY	$3.09 - $6.0 $16,584 - $32,202	5,367 Added 32.55%	21,853 $116,000
Q4 2023 Feb 09, 2024	BUY	$1.57 - $4.58 $4,298 - $12,540	2,738 Added 19.92%	16,486 $70,000
Q3 2023 Nov 13, 2023	SELL	$3.14 - $11.2 $143,523 - $511,929	-45,708 Reduced 76.88%	13,748 $53,000
Q2 2023 Aug 15, 2023	BUY	$8.45 - $12.48 $118,443 - $174,932	14,017 Added 30.85%	59,456 $601,000
Q1 2023 May 12, 2023	BUY	$9.21 - $14.98 $391,415 - $636,635	42,499 Added 1445.54%	45,439 $463,000
Q4 2022 Feb 13, 2023	SELL	$8.57 - $17.0 $18,631 - $36,958	-2,174 Reduced 42.51%	2,940 $27,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $8,113 - $11,330	-646 Reduced 11.22%	5,114 $75,000
Q2 2022 Aug 12, 2022	SELL	$10.55 - $18.81 $76,709 - $136,767	-7,271 Reduced 55.8%	5,760 $77,000
Q1 2022 May 16, 2022	SELL	$11.67 - $26.72 $121,776 - $278,823	-10,435 Reduced 44.47%	13,031 $222,000
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $323,126 - $998,712	23,466 New	23,466 $602,000

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $113M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company 2seventy Bio, Inc. Transaction History